Working Groups

From developing research programs to weighing in on legislative processes, CIMT is a community effort to facilitate and foster the research and clinical translation of cancer immunotherapies. CIMT currently hosts two working groups that address immunoguiding standards (CIMT Immunoguiding Program-CIP) and the regulatory environment of new immunotherapies (CIMT Regulatory Research Group-RRG).

CIMT also supports the reporting framework MIATA (Minimal Information About T cell Assays) that enables an objective and thorough interpretation of published results from T-cell assays. See to learn more.


The CIMT Immunoguiding Program (CIP)



The Regulatory Research Group (RRG)


Facilitating the translation of scientific knowledge from bench to bedside.